Weekend Update - W2632

▶ Explore this week’s Tape — live, sortable, drill-down →
A note from the desk: this week’s update is landing a few days late. We hit a technical problem over the weekend that took our production pipeline down. Everything below is as of Friday’s close, August 7. We’re back on the normal cadence next week. ## The Public Market Just Quoted a Price on a Drug Pipeline. The Price Was Zero.
Eighteen billion dollars of biotech changed hands inside seventy-two hours this week, and not one dollar of it was priced by the tape. That is the part worth sitting with. Not the premiums, not the CEO change, not the guidance cut. The fact that when a listed market and a private buyer looked at the same molecules on the same Monday, they came back with numbers that do not live in the same decade.
The cleanest evidence is an instrument almost nobody will look at. Curium is paying a hundred-two-fifty a share in cash for Lantheus at closing, plus up to twelve dollars a share in contingent value rights tied to clinical milestones, with the deal closing in the first half of 2027.¹ Lantheus finished the week around a hundred and one.² Read that as the market does: the cash is money-good, and the twelve dollars of clinical optionality is worth approximately nothing.
Approximately nothing.
That is not a Lantheus fact. It is a quoted, tradeable, sector-wide statement about what the public market will pay for radiopharmaceutical milestones it has not yet seen work, and the answer is that it will not pay. Every discounted-cash-flow argument about pipeline value in this space now has a live market print arguing against it, and the print says zero.
Meanwhile the buyers on the other side of that refusal are underwriting the exact same molecules at a discount rate the tape will not touch. Vertex beat the quarter, raised the year to roughly thirteen billion, and wrote a ten-billion-dollar cash check for Crinetics at eighty-five a share in the same week.³⁴⁵ It can do that because a franchise throwing off close to four billion of trailing free cash flow, marked in the Cash Flow Memo around thirty times, funds a decade-long option without going near the debt line.⁶⁷ Curium is private capital reaching the same conclusion through a different funding stack. Both transacted above where the listed market had the asset marked. The cashflow read is in Marcus’s column below; short version, Lantheus screens like a cash machine and now trades like a legal document.
And then BioNTech, which is the one that ratifies all of it. Seven times trailing free cash flow, a fourteen percent yield, a market that has effectively stopped underwriting a future at all.⁸⁹ Management’s answer was not to argue. It halved the revenue guide, replaced the co-founder in the CEO seat, said it would close manufacturing sites affecting up to eighteen hundred and sixty jobs, and authorized a billion-dollar buyback.¹⁰¹¹¹² That is a management team agreeing, in cash, with the tape’s refusal to fund its own…